A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02) Read More »
Sangami Pugazenthi Awarded 2023 ABTA Lucien Rubinstein Award for ‘Radiation Resistance in Grade 2 Meningiomas’ Read More »
Climbing Higher: Janice Armbrust’s Glioblastoma Journey at Pacific Neuroscience Institute Read More »
